Aligos Therapeutics Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that it has…
Pharmaceuticals, Biotechnology and Life Sciences
SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that it has…
Company announcement – No. 42/ 2021 ZEALAND PHARMA A/S – SHARE BUY-BACK PROGRAM UNDER SAFE HARBOUR TO AQUIRE DANISH COMMON STOCK…
– Company to focus on development of next-generation phage product candidates from ImmunoPhage platform and monoclonal antibody and nanobody programs…
CAMBRIDGE, Mass., June 28, 2021 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on…
BOSTON and JERUSALEM, June 28, 2021 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of…
Thousand Oaks, CA, June 28, 2021 (GLOBE NEWSWIRE) — CBDual Biotechnology Corp’s parent company, THC Farmaceuticals, Inc (OTC: CBDG), developer…
PRESS RELEASE AGREEMENT WITH HISTORICAL SHAREHOLDERS TO IMPLEMENT A JOINT STRATEGY TO INCREASE THE VALUE OF MASITINIB SIGNATURE OF A…
Bagsværd, Denmark, 26 June 2021 – Novo Nordisk today presented data showing that an investigational 2.0 mg dose of Ozempic®…
Intellia Therapeutics Logo Intellia Therapeutics Logo John Leonard, M.D., President and CEO, Intellia Therapeutics John Leonard, M.D., President and CEO,…
First demonstration of the survival of allogeneic iPSCs transplanted into an immunocompetent non-human primate model without the need for immune…